162 related articles for article (PubMed ID: 24333861)
1. First case of drug rash eosinophilia and systemic symptoms due to boceprevir.
Samain A; Duval-Modeste AB; Joly P; Leblanc C; Massy N; Courville P; Goria O; Riachi G
J Hepatol; 2014 Apr; 60(4):891-3. PubMed ID: 24333861
[TBL] [Abstract][Full Text] [Related]
2. Drug rash with eosinophilia and systemic symptoms due to telaprevir.
Montaudié H; Passeron T; Cardot-Leccia N; Sebbag N; Lacour JP
Dermatology; 2010; 221(4):303-5. PubMed ID: 20798484
[TBL] [Abstract][Full Text] [Related]
3. A rare and severe cutaneous adverse effect of telaprevir: drug rash with eosinophilia and systemic symptoms.
Cengiz FP; Su O; Emiroglu N; Biyik Ozkaya D; Bahali AG; Onsun N
G Ital Dermatol Venereol; 2019 Aug; 154(4):488-491. PubMed ID: 31251007
[TBL] [Abstract][Full Text] [Related]
4. Direct-acting antiviral-associated dermatitis during chronic hepatitis C virus treatment.
Biesbroeck LK; Scott JD; Taraska C; Moore E; Falsey RR; Shinohara MM
Am J Clin Dermatol; 2013 Dec; 14(6):497-502. PubMed ID: 23775427
[TBL] [Abstract][Full Text] [Related]
5. The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir.
Marks KM; Jacobson IM
Antivir Ther; 2012; 17(6 Pt B):1119-31. PubMed ID: 23188750
[TBL] [Abstract][Full Text] [Related]
6. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.
Hézode C; Fontaine H; Dorival C; Larrey D; Zoulim F; Canva V; de Ledinghen V; Poynard T; Samuel D; Bourlière M; Zarski JP; Raabe JJ; Alric L; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Métivier S; Tran A; Serfaty L; Abergel A; Causse X; Di Martino V; Guyader D; Lucidarme D; Grando-Lemaire V; Hillon P; Feray C; Dao T; Cacoub P; Rosa I; Attali P; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
J Hepatol; 2013 Sep; 59(3):434-41. PubMed ID: 23669289
[TBL] [Abstract][Full Text] [Related]
7. Telaprevir-induced DRESS.
Kesar V; Kesar V; Khaitova V; Motamed D; Schiano T
J Drugs Dermatol; 2014 Feb; 13(2):199-200. PubMed ID: 24509972
[TBL] [Abstract][Full Text] [Related]
8. Anemia management in patients with chronic viral hepatitis C.
Hynicka LM; Heil EL
Ann Pharmacother; 2013 Feb; 47(2):228-36. PubMed ID: 23386076
[TBL] [Abstract][Full Text] [Related]
9. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.
Chen EY; Sclair SN; Czul F; Apica B; Dubin P; Martin P; Lee WM
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1014-20.e1-2. PubMed ID: 23602817
[TBL] [Abstract][Full Text] [Related]
10. Telaprevir to boceprevir switch highlights lack of cross-reactivity.
Carlson A; Gregorich Z; Striker R
Clin Infect Dis; 2013 Feb; 56(4):552-4. PubMed ID: 23166191
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
[TBL] [Abstract][Full Text] [Related]
12. Severe cutaneous adverse reaction to telaprevir.
Shuster M; Do D; Nambudiri V
Dermatol Online J; 2015 Jan; 21(1):. PubMed ID: 25612120
[TBL] [Abstract][Full Text] [Related]
13. Boceprevir.
Prescrire Int; 2012 Apr; 21(126):89-92. PubMed ID: 22515132
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.
Coilly A; Roche B; Dumortier J; Leroy V; Botta-Fridlund D; Radenne S; Pageaux GP; Si-Ahmed SN; Guillaud O; Antonini TM; Haïm-Boukobza S; Roque-Afonso AM; Samuel D; Duclos-Vallée JC
J Hepatol; 2014 Jan; 60(1):78-86. PubMed ID: 23994384
[TBL] [Abstract][Full Text] [Related]
15. Telaprevir.
Prescrire Int; 2012 Apr; 21(126):93-6. PubMed ID: 22515133
[TBL] [Abstract][Full Text] [Related]
16. Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3.
Silva MO; Treitel M; Graham DJ; Curry S; Frontera MJ; McMonagle P; Gupta S; Hughes E; Chase R; Lahser F; Barnard RJ; Howe AY; Howe JA
J Hepatol; 2013 Jul; 59(1):31-7. PubMed ID: 23454058
[TBL] [Abstract][Full Text] [Related]
17. Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.
Seden K; Back D
Curr Opin HIV AIDS; 2011 Nov; 6(6):514-26. PubMed ID: 22001895
[TBL] [Abstract][Full Text] [Related]
18. Preparation of HCV infected patients to the triple therapy with first generation protease inhibitors.
Kozielewicz D; Halota W; Dybowska D
Przegl Epidemiol; 2013; 67(4):623-8,713-6. PubMed ID: 24741907
[TBL] [Abstract][Full Text] [Related]
19. Future of hepatitis C therapy: development of direct-acting antivirals.
Dore GJ; Matthews GV; Rockstroh J
Curr Opin HIV AIDS; 2011 Nov; 6(6):508-13. PubMed ID: 21897228
[TBL] [Abstract][Full Text] [Related]
20. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.
Butt AA; Kanwal F
Clin Infect Dis; 2012 Jan; 54(1):96-104. PubMed ID: 22156853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
